Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, Malcolm Kuno and Caleb Smith from the team. Our next presenting company is Apellis and presenting on behalf of the company, we have CEO Cedric Francois. I want to remind the attendees of this session to use the Ask the question feature in the portal, and I would be happy to ask the question on your behalf. With that, Cedric, take it away.
Thank you so much, Anupam, and thank you for inviting us again to this conference. I wished it was in person, but hopefully next year, that will be the case. So starting with our first slide, Slide #2 are forward-looking statements. And going to Slide #3. First, taking a quick look back at year 2021, which was an extraordinary year for us. We continued to position ourselves to be the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |